Upload Avatar (500 x 500)
Hongyang Wang
Mayo Clinic College of Medicine
University of Science and Technology of China
Shanghai
Language: Chinese, English, German
Tumorigenesis
Inflammation
Metabolism
Molecular Mechanisms
Regulatory Networks
Cancer Stem Cells
Hepatobiliary Tumors
Early Diagnosis
Molecular Typing
Personalized Treatment
Areas of Focus
- Molecular mechanisms and regulatory networks promoting tumorigenesis and development in inflammation and metabolism
- Signal regulation of cancer stem cells and its significance in hepatobiliary tumors
- Early diagnosis, molecular typing, and personalized treatment of tumors (digestive system tumors, urinary system tumors, etc.)
Work Experience
- 2013.02-present - National Liver Cancer Science Center - Director
Academic Background & Achievements
- 1989.06-1992.09 PhD in Clinical Biochemistry: University of Ulm
- Academician of the Chinese Academy of Engineering
- Academician of the World Academy of Sciences for the advancement of science in developing countries
- Founder Director of the National Liver Cancer Science Center
- Published over 300 papers in influential journals like Cell, Cancer Cell, Science Translational Medicine
- Received 14 invention patents in the last five years
Publications
- The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis., Hongyang Wang* et al., 2023
- Immune index: A gene and cell prognostic signature for immunotherapy response prediction in hepatocellular carcinoma., Hongyang Wang* et al., 2023
- PTEN Deficiency Facilitates Exosome Secretion and Metastasis in Cholangiocarcinoma by Impairing TFEB-mediated Lysosome Biogenesis., Hongyang Wang* et al., 2023
- To be or not to be: The double-edged sword roles of liver progenitor cells., Hongyang Wang* et al., 2023
- m6A RNA methylation-mediated upregulation of HLF promotes intrahepatic cholangiocarcinoma progression by regulating the FZD4/β-catenin signaling pathway., Hongyang Wang* et al., 2023
- Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma., Hongyang Wang* et al., 2023
- Single-cell dissection of remodeled inflammatory ecosystem in primary and metastatic gallbladder carcinoma., Hongyang Wang* et al., 2022
- Integrated Multi-Omics Landscape of Liver Metastases., Hongyang Wang* et al., 2022
Awards
- Wu Jieping Medical Award (2021): Wu Jieping Medical Foundation
- National Innovation Award Medal (2020): Ministry of Human Resources and Social Security, China Association for Science and Technology, Ministry of Science and Technology, State-owned Assets Supervision and Administration Commission of the State Council
- Shanghai Medical Development Outstanding Contribution Award (2017): Shanghai Medical Association
- Second Tree-Lan Medical Award (2015): Shusen-Lanjuan Academician Talent Fund Council
- New Discovery of Molecular Mechanism of Malignant Transformation of Liver Inflammation (2014): Shanghai Municipal Government
